The present application is directed to novel P2X7R antagonists that are N-indol-3-yl- acetamide and N-azaindol-3-yl-acetamide compounds, pharmaceutical compositions comprising the same and their use for the prophylactic or therapeutic treatment of diseases mediated by P2X7R activity.Spoj opće formule: naznačen time da, - R1 je mono- ili bicikloalkilalkilna skupina ili mono- ili bicikloalkilna skupina; - R2 je odabran od ravnog ili razgranatog C1-C5 alkila koji može proizvoljno biti supstituiran sa -OH, -CH2-OH,